ViaLase, Inc. , A clinical-stage medical technology startup called has raised $40 million in a series C round of funding with the goal of filling gaps in the current paradigm for treating glaucoma.
The financing was spearheaded by a new investor, with backing from existing investors such as Arboretum Ventures, Venture Investors Health Fund, and Falcon Vision, an ophthalmology investment platform backed by KKR.
The company, led by its founder and CEO, Tibor Juhasz, PhD, plans to use the money to make sure that the ViaLase® Laser* continues to advance clinically, legally, and commercially. The first femtosecond laser used to treat primary open angle glaucoma (POAG) will be the ViaLase Laser, if approved.
Read also – Blue Yonder deaclares an Agreement To Acquire One Network Enterprises
Femtosecond laser image-guided high-precision trabeculotomy (FLigHT), a noninvasive glaucoma treatment, is made possible by the ViaLase Laser by combining femtosecond laser technology with micron-level image guiding.
Using a noninvasive, nonsurgical method to create channels in the trabecular meshwork (TM) to lower intraocular pressure (IOP), the new FLigHT procedure will provide doctors increased vision and precision.
About ViaLase, Inc.
The ViaLuxeTM Laser System is intended to lower intraocular pressure (IOP) by non-invasively creating customised drainage channels via the trabecular meshwork combining femtosecond laser accuracy and micron-accurate gonio imaging.
Read also – Boston-based InStride Health Secures $30Million in Series B Round Funding
